Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.

@article{Amparo2013TopicalI1,
  title={Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.},
  author={Francisco Amparo and Mohammad H Dastjerdi and Andre Okanobo and Giulio Ferrari and Leila Smaga and Pedram Hamrah and Ula V Jurkunas and Debra A. Schaumberg and Reza Dana},
  journal={JAMA ophthalmology},
  year={2013},
  volume={131 6},
  pages={
          715-723
        }
}
IMPORTANCE The immunopathogenic mechanisms of dry eye disease (DED), one of the most common ophthalmic conditions, is incompletely understood. Data from this prospective, double-masked, randomized trial demonstrate that targeting interleukin 1 (IL-1) by topical application of an IL-1 antagonist is efficacious in significantly reducing DED-related patient symptoms and corneal epitheliopathy. OBJECTIVE To evaluate the safety and efficacy of treatment with the topical IL-1 receptor antagonist… CONTINUE READING
BETA
Highly Cited
This paper has 59 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS, ESTIMATED 52% COVERAGE

60 Citations

051015'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 60 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Evaluation of topical cyclosporine JAMA OPHTHALMOL PUBLISHED

  • HD Perry, R Solomon, ED Donnenfeld
  • ONLINE APRIL 18,
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…